The Evolution of Cardiometabolic Risk Reduction and Mixed Dyslipidemia: Examining the Role of Chronic Obesity Management

Program 204-000-08-469-L01P
1.0 hour (0.1 CEU) of continuing education credit

Program Overview

Learn about trends in the prevalence and the clinical and economic impact of coronary heart disease (CHD), obesity, mixed dyslipidemia, and the metabolic syndrome in the United States. Current recommendations for managing obesity and mixed dyslipidemia will be reviewed briefly. Limitations of lifestyle modification and currently available anti-obesity and antilipemic drug therapies, and the mechanisms of action and possible benefits of new drug therapies in development will be discussed. Case studies will be used to illustrate the decision-making process for patients at risk for CHD because of obesity or mixed dyslipidemia.

Program Faculty

Joseph Saseen, Pharm.D., FCCP, BCPS, CLS
Associate Professor of Clinical Pharmacy and Family Medicine
University of Colorado Denver
Aurora, Colorado

Carrie M. Maffeo, Pharm.D., BCPS, CDE
Director, Health Education Center
Assistant Professor of Pharmacy Practice
Butler University College of Pharmacy and Health Sciences
Indianapolis, Indiana

Learning Objectives

At the conclusion of this program, participants should be able to

Discuss trends in the prevalence and the clinical and economic impact of coronary heart disease (CHD), obesity, mixed dyslipidemia, and the metabolic syndrome in the United States.
Outline current recommendations for managing obesity and mixed dyslipidemia, as well as the limitations and benefits of lifestyle modification and currently available drug therapies for the treatment of these conditions.
Recommend an appropriate therapeutic strategy to reduce CHD risk in a patient with obesity or mixed dyslipidemia.
Discuss the pharmacist's role in reducing cardiovascular risk and promoting a healthy lifestyle.